News

Although gene therapy is now “a clinical reality,” it still remains an early stage therapeutic modality. That’s the view of Caroline Man Xu, CEO and co-founder of Vigeneron GmbH, a German gene therapy company that has maintained a low profile while steadily staking out a promising position in gene therapies for inherited retinal disease.– Full […]

Follow-on collaboration between ViGeneron and Daiichi Sankyo allows the companies to create and validate vgAAV-based therapeutic candidates ViGeneron and Daiichi Sankyo have agreed a follow-on collaboration to evaluate ViGeneron’s adeno-associated virus vectors (vGAAVs) for delivering Daiichi Sankyo’s novel therapeutic protein to treat prevalent eye diseases. The two companies have been working on a programme together […]

Regeneron beefed up its gene therapy capabilities Wednesday, signing a new deal with the German biotech ViGeneron. The similarly named — but unrelated — companies announced the collaboration early Wednesday morning, one which would see ViGeneron receive undisclosed upfront and milestone payments in exchange for Regeneron getting access to its suite of recombinant adeno-associated virus […]

Dive Brief: • Through a deal announced Wednesday, a German-based biotechnology company has agreed to help Regeneron develop a gene therapy for an inherited retinal disease. • The company, ViGeneron, claims to have an improved method for engineering the viral vehicles often used to shuttle genetic medicine into the proper cells. So far, ViGeneron’s research […]

Regeneron is dipping its toe deeper into the gene therapy waters, teaming up with ViGeneron to work on a retinal disease prospect based on engineered recombinant adeno-associated virus vectors (vgAAVs). While best known for its antibody work, Regeneron has a history of exploring other modalities through dealmaking, inking a $640 million gene therapy pact with Avalanche […]

ViGeneron GmbH is collaborating with Biogen Inc. to develop gene therapies for the treatment of inherited eye diseases. The companies will use Germany-based ViGeneron’s proprietary vgAAV gene therapy vector technology to efficiently transduce retinal cells by injecting medicine into the eye. ViGeneron, a gene therapy developer, will focus on optimizing and validating therapies for an […]

Almost two years after Biogen swooped again into the ophthalmic gene therapy field with an $800 million buyout of eye-focused Nightstar Therapeutics, it’s turning to a young player for a new program. Germany’s ViGeneron will be deploying its next-generation AAV vectors to generate candidates for a target — Biogen isn’t disclosing which exactly — that […]

ViGeneron, a gene therapy company, and WuXi Advanced Therapies, a contract, testing, development, and manufacturing organization (CTDMO), entered into a strategic partnership to accelerate production for the clinical development of VG901, a next-generation ophthalmic gene therapy program. ViGeneron’s lead product, VG901, targets a disease gene for Retinitis pigmentosa (RP), for which there is currently no […]

Germany’s ViGeneron is to advance development of its next-generation ophthalmology gene therapy pipeline after a series A financing round. The privately-owned Munich-based biotech did not say how much it had raised from the financing round, which was led by WuXi AppTec and Sequoia Capital China. But ViGeneron said the proceeds will allow it to accelerate […]